Shares of Context Therapeutics Inc. rose over 7% in Wednesday's pre-market trading after JMP Securities initiated coverage with an 'Outperform' rating and a price target of $4.

Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today announced the appointment of Andy ...

Shares of Context Therapeutics Inc. (NASDAQ:CNTX – Get Free Report) have earned a consensus rating of “Buy” from the seven brokerages that are covering the stock, MarketBeat.com reports.

PHILADELPHIA, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid ...

JMP Securities initiated coverage of Context Therapeutics (CNTX) with an Outperform rating and $4 price target Context is a $97.8M market cap clinical-stage biotechnology company focused on ...

Context Therapeutics has a one year low of $0.89 and a one year high of $2.75. The company has a market cap of $81.00 million, a P/E ratio of -1.19 and a beta of 2.10.

Context Therapeutics (CNTX) announced the appointment of Andy Pasternak as Chairman of its Board of Directors, succeeding Richard Berman, who ...

PHILADELPHIA, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid ...